Your browser doesn't support javascript.
loading
CRISPR/Cas9-mediated excision of ALS/FTD-causing hexanucleotide repeat expansion in C9ORF72 rescues major disease mechanisms in vivo and in vitro.
Meijboom, Katharina E; Abdallah, Abbas; Fordham, Nicholas P; Nagase, Hiroko; Rodriguez, Tomás; Kraus, Carolyn; Gendron, Tania F; Krishnan, Gopinath; Esanov, Rustam; Andrade, Nadja S; Rybin, Matthew J; Ramic, Melina; Stephens, Zachary D; Edraki, Alireza; Blackwood, Meghan T; Kahriman, Aydan; Henninger, Nils; Kocher, Jean-Pierre A; Benatar, Michael; Brodsky, Michael H; Petrucelli, Leonard; Gao, Fen-Biao; Sontheimer, Erik J; Brown, Robert H; Zeier, Zane; Mueller, Christian.
Afiliación
  • Meijboom KE; Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, 01605, USA.
  • Abdallah A; Department of Neurology, University of Massachusetts Medical School, Worcester, MA, 01605, USA.
  • Fordham NP; Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, 01605, USA.
  • Nagase H; Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, 01605, USA.
  • Rodriguez T; Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, 01605, USA.
  • Kraus C; RNA Therapeutics Institute and Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, 01605, USA.
  • Gendron TF; RNA Therapeutics Institute and Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, 01605, USA.
  • Krishnan G; Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.
  • Esanov R; Department of Neurology, University of Massachusetts Medical School, Worcester, MA, 01605, USA.
  • Andrade NS; Department of Psychiatry & Behavioral Sciences, Center for Therapeutic Innovation, University of Miami Miller School of Medicine, Miami, FL, 33136, USA.
  • Rybin MJ; Department of Psychiatry & Behavioral Sciences, Center for Therapeutic Innovation, University of Miami Miller School of Medicine, Miami, FL, 33136, USA.
  • Ramic M; Department of Psychiatry & Behavioral Sciences, Center for Therapeutic Innovation, University of Miami Miller School of Medicine, Miami, FL, 33136, USA.
  • Stephens ZD; Department of Psychiatry & Behavioral Sciences, Center for Therapeutic Innovation, University of Miami Miller School of Medicine, Miami, FL, 33136, USA.
  • Edraki A; Department of Quantitative Health Sciences. Mayo Clinic, Rochester, MN, 55905, USA.
  • Blackwood MT; RNA Therapeutics Institute and Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, 01605, USA.
  • Kahriman A; Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, 01605, USA.
  • Henninger N; Department of Neurology, University of Massachusetts Medical School, Worcester, MA, 01605, USA.
  • Kocher JA; Department of Neurology, University of Massachusetts Medical School, Worcester, MA, 01605, USA.
  • Benatar M; Department of Quantitative Health Sciences. Mayo Clinic, Rochester, MN, 55905, USA.
  • Brodsky MH; Department of Neurology, University of Miami Miller School of Medicine, Miami, FL, 33136, USA.
  • Petrucelli L; Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, MA, 01605, USA.
  • Gao FB; Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.
  • Sontheimer EJ; Department of Neurology, University of Massachusetts Medical School, Worcester, MA, 01605, USA.
  • Brown RH; RNA Therapeutics Institute and Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, 01605, USA.
  • Zeier Z; Department of Neurology, University of Massachusetts Medical School, Worcester, MA, 01605, USA.
  • Mueller C; Department of Psychiatry & Behavioral Sciences, Center for Therapeutic Innovation, University of Miami Miller School of Medicine, Miami, FL, 33136, USA. zzeier@med.miami.edu.
Nat Commun ; 13(1): 6286, 2022 10 21.
Article en En | MEDLINE | ID: mdl-36271076
ABSTRACT
A GGGGCC24+ hexanucleotide repeat expansion (HRE) in the C9ORF72 gene is the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), fatal neurodegenerative diseases with no cure or approved treatments that substantially slow disease progression or extend survival. Mechanistic underpinnings of neuronal death include C9ORF72 haploinsufficiency, sequestration of RNA-binding proteins in the nucleus, and production of dipeptide repeat proteins. Here, we used an adeno-associated viral vector system to deliver CRISPR/Cas9 gene-editing machineries to effectuate the removal of the HRE from the C9ORF72 genomic locus. We demonstrate successful excision of the HRE in primary cortical neurons and brains of three mouse models containing the expansion (500-600 repeats) as well as in patient-derived iPSC motor neurons and brain organoids (450 repeats). This resulted in a reduction of RNA foci, poly-dipeptides and haploinsufficiency, major hallmarks of C9-ALS/FTD, making this a promising therapeutic approach to these diseases.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Demencia Frontotemporal / Esclerosis Amiotrófica Lateral Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Demencia Frontotemporal / Esclerosis Amiotrófica Lateral Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos